[go: up one dir, main page]

AR100846A1 - FORMULACIONES INTRAVAGINALES QUE COMPRENDEN GnRH - Google Patents

FORMULACIONES INTRAVAGINALES QUE COMPRENDEN GnRH

Info

Publication number
AR100846A1
AR100846A1 ARP150101903A ARP150101903A AR100846A1 AR 100846 A1 AR100846 A1 AR 100846A1 AR P150101903 A ARP150101903 A AR P150101903A AR P150101903 A ARP150101903 A AR P150101903A AR 100846 A1 AR100846 A1 AR 100846A1
Authority
AR
Argentina
Prior art keywords
acid
formulation
intravaginal
gnrh
amount
Prior art date
Application number
ARP150101903A
Other languages
English (en)
Inventor
P Kolbasa Karen
A Wicks Nicholas
C Sucheta Susan
Luo Laibin
L Feenstra Kenneth
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of AR100846A1 publication Critical patent/AR100846A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/02Suppositories; Bougies; Bases therefor; Ovules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Formulación intravaginal, que comprende un ácido carboxílico en una cantidad del 10 - 20% peso/peso de dicha formulación, una base oleaginosa, que tiene una temperatura de fusión entre 30ºC y 38ºC, GnRH o uno de sus análogos, en una cantidad equivalente a la cantidad de GnRH de entre 10 mg y 600 mg. También se proporciona un método para inducir ovulación en un rumiante usando la formulación. Reivindicación 15: La formulación intravaginal de una cualquiera de las reivindicaciones 1 - 14, caracterizada porque el ácido carboxílico está seleccionado entre el grupo que consiste en ácido cítrico, ácido succínico, ácido tartárico, ácido glicólico, ácido ascórbico, ácido láctico, ácido aspártico, edetato de dipotasio o una de sus combinaciones. Reivindicación 16: La formulación intravaginal de la reivindicación 15, caracterizada porque dicho ácido carboxílico es ácido cítrico.
ARP150101903A 2014-06-16 2015-06-15 FORMULACIONES INTRAVAGINALES QUE COMPRENDEN GnRH AR100846A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462012523P 2014-06-16 2014-06-16

Publications (1)

Publication Number Publication Date
AR100846A1 true AR100846A1 (es) 2016-11-02

Family

ID=53773489

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101903A AR100846A1 (es) 2014-06-16 2015-06-15 FORMULACIONES INTRAVAGINALES QUE COMPRENDEN GnRH

Country Status (14)

Country Link
US (1) US20170143786A1 (es)
EP (1) EP3154519A1 (es)
JP (1) JP2017519769A (es)
CN (1) CN106456705A (es)
AR (1) AR100846A1 (es)
AU (1) AU2015277613A1 (es)
BR (1) BR112016028875A2 (es)
CA (1) CA2951532A1 (es)
CL (1) CL2016003220A1 (es)
IL (1) IL249121A0 (es)
MX (1) MX2016016768A (es)
RU (1) RU2016146994A (es)
UY (1) UY36168A (es)
WO (1) WO2015195333A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11376220B2 (en) * 2017-06-30 2022-07-05 Therio, LLC Single-injection methods and formulations to induce and control multiple ovarian follicles in bovine, caprine, ovine, camelid and other female animals

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211769A (en) * 1977-08-24 1980-07-08 Takeda Chemical Industries, Ltd. Preparations for vaginal administration
US5985320A (en) * 1996-03-04 1999-11-16 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
CN101692985A (zh) * 2009-09-29 2010-04-14 浙江大学 一种诱导奶牛定时排卵进行人工授精的方法
CN101779988A (zh) * 2010-02-03 2010-07-21 李树静 一种青年牛高强度重复超数排卵的方法

Also Published As

Publication number Publication date
CA2951532A1 (en) 2015-12-23
EP3154519A1 (en) 2017-04-19
MX2016016768A (es) 2017-04-04
BR112016028875A2 (pt) 2017-08-22
US20170143786A1 (en) 2017-05-25
RU2016146994A3 (es) 2018-07-16
CL2016003220A1 (es) 2017-06-02
IL249121A0 (en) 2017-01-31
AU2015277613A1 (en) 2016-12-08
UY36168A (es) 2016-01-29
WO2015195333A1 (en) 2015-12-23
CN106456705A (zh) 2017-02-22
JP2017519769A (ja) 2017-07-20
RU2016146994A (ru) 2018-07-16

Similar Documents

Publication Publication Date Title
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
MX2017002670A (es) Inhibidores de glucosidasa.
MX388562B (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
CL2018001478A1 (es) Agonistas del receptor de apelina y métodos de uso
CL2015002628A1 (es) Compuestos de heteroarilo y sus usos.
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
EA201891489A1 (ru) Фармацевтическая композиция, содержащая аморфный леналидомид и антиоксидант
MX2018005136A (es) Sales de valbenazina y polimorfos de las mismas.
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
CL2018001621A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)
MX2017003121A (es) Formulaciones de anticuerpos.
CL2017000071A1 (es) Acidos carboxílicos hterocíclicos como activadores de guanilato ciclasa soluble.
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
PE20181040A1 (es) Formulacion solida oral que contiene irinotecan y metodo de preparacion de la misma
UY36118A (es) Compuestos y composiciones para inducir condrogénesis
CO2019011546A2 (es) Compuestos y métodos para el tratamiento de enfermedades parasitarias
AR101414A1 (es) Derivados de pirrolidinona como inhibidores de metap-2
MX2021014139A (es) Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht1f.
EA201990998A1 (ru) Фармацевтические составы и способы их получения
MX390651B (es) Compuestos para el tratamiento de trastornos hipoproliferativos
PE20200794A1 (es) Composicion para su uso en la prevencion y el tratamiento de patologias del aparato cardiovascular
UY37904A (es) Composiciones y métodos para mejorar la utilización de nitrógeno en un rumiante
MX379679B (es) Composiciones para el cuidado personal.

Legal Events

Date Code Title Description
FB Suspension of granting procedure